| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Regeneus Ltd (ASX: RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell-based therapies to address significant unmet medical needs in the human and veterinary health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company has three technology platforms - Progenza, an allogeneic "off-the-shelf" adipose stem cell therapy to treat osteoarthritis and other musculoskeletal conditions, RGSH4k, an autologous therapeutic cancer vaccine to treat a wide range of cancer types and Sygenus, stem cell secretions based cream targeting acne and other inflammatory skin conditions. The company has two therapies targeting animal conditions: CryoShot, a clinical-stage allogeneic "off-the-shelf" adipose stem cell therapy for the treatment of canine and equine osteoarthritis and other musculoskeletal conditions and Kvax, an autologous therapeutic cancer vaccine in clinical trials. |
| Category: | Health & biotech |
| URL: | http://regeneus.com.au/ |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | RGS |
| Year of Commencement: | 2007 |
| Address: | Pymble, New South Wales |
| State: | New South Wales |
| Overseas Operations: | No |
| Twitter: | Tweets by @Regeneus |
| Facebook: | https://www.facebook.com/pages/Regeneus/110433905646491 |
| Linkedin: | https://www.linkedin.com/company/regeneus-ltd |
| Founders: | |
| Awards won: | |
